BioCryst Pharmaceuticals
BCRX
BCRX
134 hedge funds and large institutions have $245M invested in BioCryst Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
1% less funds holding
Funds holding: 136 → 134 (-2)
9.59% less ownership
Funds ownership: 89.1% → 79.51% (-9.6%)
48% less capital invested
Capital invested by funds: $473M → $245M (-$228M)
Holders
134
Holding in Top 10
1
Calls
$3.05M
Puts
$396K
Top Buyers
| 1 | +$7M | |
| 2 | +$6.01M | |
| 3 | +$5.28M | |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$4.18M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.54M |
Top Sellers
| 1 | -$10.7M | |
| 2 | -$9.06M | |
| 3 | -$7.52M | |
| 4 |
Millennium Management
New York
|
-$6.98M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.15M |